<DOC>
	<DOCNO>NCT00009659</DOCNO>
	<brief_summary>This study examine safety effectiveness synthetic hormone , CDB-2914 , treat symptom menopause . It compare effect estrogen CDB-2914 estrogen progesterone postmenopausal woman . The study also evaluate whether CDB-2914 affect adrenal gland function . CDB-2914 chemically similar cortisol , hormone produce adrenal gland regulate body 's response stress , infection injury . Healthy woman volunteer age 45 70 menstrual period year , currently take hormone replacement therapy , smoke hysterectomy may eligible study . Candidates provide medical history physical examination , include breast pelvic exam . They also provide blood sample , mammogram pap smear , instruct dietary source and/or supplement require sure consume least 1,000 mg. calcium day . Participants randomly assign take : ) estrogen plus CDB-2914 , b ) estrogen plus progesterone , c ) estrogen plus placebo ( look-alike tablet active ingredient ) daily mouth 6 week . During study period , keep record symptom , vaginal bleeding , medicine take . They return NIH Clinical Center weekly blood test fill questionnaire mood , appetite , sleep pattern , menopausal symptom , quality life issue . At 6-week visit , participant : - Bring 24-hour urine collection - Have vaginal ultrasound evaluate effect medication thickness endometrium ( line uterus ) - Bring bottle study medication pill count - Discuss unusual troubling symptom study nurse physician A final visit schedule 1 3 week 6-week visit , participant turn calendar daily symptom return unused progesterone pill .</brief_summary>
	<brief_title>Use Synthetic Hormone CDB-2914 Treating Symptoms Menopause</brief_title>
	<detailed_description>Doctors recommend hormone replacement therapy postmenopausal woman treatment symptom estrogen-deficiency . However , many woman take hormone replacement therapy side effect . In woman intact uterus , estrogen must give progesterone prevent overgrowth line uterus . Side effect progesterone may cause woman discontinue hormone replacement therapy . Compounds similar naturally occur hormone synthesize studied ability block simulate action sex steroid estrogen progesterone . The development class compound , call selective hormone receptor modulators , may provide new treatment target specific organ tissue . One example selective estrogen receptor modulator raloxifene , block estrogen action uterus , act like estrogen bone . Raloxifene approve use post-menopausal woman form hormone replacement therapy treatment osteoporosis . It provide many estrogen 's benefit without stimulate uterine line thus may take without progestin . This study evaluate selective progesterone receptor modulator CDB-2914 , man-made hormone . Other progesterone receptor modulators show block estrogen 's stimulating effect uterus monkey . If CDB-2914 effect menopausal woman , may provide new approach hormone replacement therapy . In woman study NIH , single dose CDB-2914 slow uterine development induce menses , depend give menstrual cycle . Like raloxifene , CDB-2914 potential use hormone replacement therapy , date effect chronic administration study . This study aim evaluate safety physiologic endocrine effect chronic oral administration CDB-2914 postmenopausal woman . All study subject receive daily oral estrogen either CDB-2914 , progesterone placebo evaluate whether CDB-2914 block enhance usual effect hormone replacement therapy uterine lining , lipid level , clot factor , bone turnover , hot flash quality life . Weekly blood measurement , quality life questionnaire , pre- post-treatment ultrasound examination uterus single biopsy uterine lining perform study subject assess endpoint .</detailed_description>
	<mesh_term>Progesterone</mesh_term>
	<criteria>Participants must female gender . Participants age must 4570 year inclusive . Participants FSH must great 20 mlU/mL assay ( twosite immunofluorescent assay , Abbott Labs , postmenopausal range great 20 ) . Participants must have12 month great history amenorrhea . No current use sex steroid hormone replacement therapy ( include selective estrogen receptor modulators ) include transdermal , injectable , vaginal oral preparation willingness abstain use study . Participants BMI 1930 . Participants must normal mammogram pap smear study entry . Participants must able willing maintain minimum daily intake 1000 mg calcium dietary source and/or supplement duration study . Participants must normal protime PTT screen visit . Participants must able read speak English fluently allow accurate selfadministration medication , record symptom unassisted completion weekly questionnaire . Participants must good health . Chronic medication use , except glucocorticoid use sex hormone replacement therapy , may acceptable discretion principal investigator . Interval use overthecounter counter drug , aspirin NSAIDs , acceptable must record . Particippants hemoglobin must great 10 g/dL . Participants must willing able selfadminister daily medication , complete selfadministered questionnaire , record daily symptom return Clinical Center weekly followup appointment minimum 8 continuous week . Participants history diabetes mellitus type I II eligible . Participants history malignancy within past 5 year eligible . Participants must current use ( within 90 day study entry ) drug affect bone turnover mineral metabolism bisphophonates , parathyroid hormone , hydrochlorothiazide calcitonin . Participants triglyceride level 500 mg/ml great initial visit eligible . Participants must use cholesterollowering medication currently within 6 week study entry . Participants tobacco use currently within 90 day study entry eligible . Participants history disease alter mineral metabolism hyperparathyroidism , chronic renal insufficiency hemodialysis eligible . Participants require ongoing antiinflammatory medication ( e.g. , aspirin , NSAIDs ) whether prescribe counter eligible . Participants current use anticoagulant ( e.g . Warfarin , heparin ) , antiplatelet drug history bleed disorder eligible . Participants must use OTC herbal alternative treatment hot flash menopausal symptom , DHEA , soy protein supplement , phytoestrogens within two month study entry , unwillingness abstain product study . Participants must use drug affect frequency intensity hot flash clonidine SSRI 's within 2 month study entry . Participants must ischemic heart disease ( e.g . angina , myocardial infarction congestive heart failure ) . Participants must significant abnormality history , physical laboratory examination . Participants must history venous thromboembolic event include deep vein thrombosis ( DVT ) , pulmonary embolism , retinal vein thrombosis . Participants must history stroke , complicate migraine , document transient ischemic attack uncontrolled hypertension . Participants must absence uterus ( hysterectomy ) .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2001</verification_date>
	<keyword>Endometrium</keyword>
	<keyword>Estrogen</keyword>
	<keyword>Antihormone</keyword>
	<keyword>Menopause</keyword>
	<keyword>Progesterone</keyword>
	<keyword>Postmenopausal Women</keyword>
	<keyword>Hormone Replacement</keyword>
</DOC>